Haohai Biological Technology Bundle
Who Owns Haohai Biological Technology Company?
Understanding a company's ownership is key to grasping its strategy and accountability. Haohai Biological Technology's dual listing on the Hong Kong Stock Exchange in 2015 and the Shanghai Stock Exchange's Sci-tech Innovation Board in 2019 marked significant shifts in its shareholder landscape.
Founded in 2007, this biomedical innovator focuses on medical devices and biomaterials, including products for ophthalmology. As of March 31, 2025, its market capitalization stood at approximately HK$12.57 billion.
The ownership structure of Haohai Biological Technology is a complex interplay of its founding stakes, evolving shareholding, major investors, and public shareholders, all of whom influence its direction. Examining these elements provides insight into who ultimately controls this prominent entity in the biotechnology sector.
Who Founded Haohai Biological Technology?
Shanghai Haohai Biological Technology Co., Ltd. was established on January 24, 2007, and later transitioned into a joint stock company on August 2, 2010. The initial ownership structure was defined by the contributions of its key founders, setting the stage for its development in the biomedical sector.
| Founder | Initial Shares Held | Initial Percentage of Ownership |
|---|---|---|
| Ms. You Jie | 28,800,000 | 24.00% |
| Mr. Lou Guoliang | 10,000,000 | 8.33% |
| Dr. Hou Yongtai | 6,000,000 | 5.00% |
Founding of the Company
Shanghai Haohai Biological Technology Co., Ltd. commenced operations on January 24, 2007. Its transformation into a joint stock company occurred on August 2, 2010.
Key Founding Shareholders
Ms. You Jie was a significant early shareholder, holding 24.00% of the initial ordinary shares. Mr. Lou Guoliang also held a substantial stake, representing 8.33% of the total.
Dr. Hou Yongtai's Role
Dr. Hou Yongtai joined the company in 2007 and subscribed to 6,000,000 shares, representing 5.00% of the initial capital. He currently serves as the Chairman of the Board.
Mr. Wu Jianying's Contribution
Mr. Wu Jianying also joined in 2007, bringing expertise in medical service and general surgery. He plays a vital role as an Executive Director and General Manager.
Early Ownership Structure
The initial share distribution among founders reflects their foundational roles. Specific details on early agreements like vesting schedules are not widely publicized.
Biomedical Sector Focus
The early ownership was instrumental in shaping the company's strategic direction within the biomedical industry. This foundation guided its growth and market positioning.
The early ownership of Shanghai Haohai Biological Technology Co., Ltd. was characterized by the significant stakes held by its founders, Ms. You Jie, Mr. Lou Guoliang, and Dr. Hou Yongtai, alongside the contributions of Mr. Wu Jianying. This initial distribution of shares, totaling 24.00% for Ms. You Jie, 8.33% for Mr. Lou Guoliang, and 5.00% for Dr. Hou Yongtai, underscored their commitment and vision for the company's trajectory in the biomedical field. While detailed information regarding early agreements such as vesting schedules or buy-sell clauses among these individuals is not extensively documented in public records, the foundational ownership structure clearly reflects their pivotal roles in establishing the company's direction and operations. Understanding this early ownership is key to grasping the company's initial corporate governance and the influence of its founding members. For a broader understanding of the market landscape, exploring the Competitors Landscape of Haohai Biological Technology can provide valuable context.
Founders and Initial Shareholdings
The company's inception saw key individuals taking substantial ownership stakes, laying the groundwork for its future operations and strategic decisions.
- Ms. You Jie: 28,800,000 shares (24.00%)
- Mr. Lou Guoliang: 10,000,000 shares (8.33%)
- Dr. Hou Yongtai: 6,000,000 shares (5.00%)
- Mr. Wu Jianying: Executive Director and General Manager
Haohai Biological Technology SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Haohai Biological Technology’s Ownership Changed Over Time?
The ownership journey of Haohai Biological Technology has been shaped by strategic public offerings, beginning with its H share listing on the Hong Kong Stock Exchange in April 2015. This was followed by an A Share Offering and listing on the Shanghai Stock Exchange's Sci-tech Innovation Board in October 2019, significantly altering its shareholder base and increasing its public float.
| Event | Date | Details |
|---|---|---|
| H Share Listing | April 30, 2015 | Initial issuance of 40,000,000 H shares |
| Additional H Shares | May 2015 | Issuance of 45,300 H shares |
| A Share Offering & Listing | October 30, 2019 | Issuance of 17,800,000 Domestic Shares on Shanghai Stock Exchange |
| Post-A Share Offering Share Count | October 30, 2019 | Total issued shares: 177,845,300 (40,045,300 H shares, 137,800,000 A shares) |
As of December 31, 2023, the ultimate controlling shareholders of Haohai Biological Technology are identified as Mr. Jiang Wei and his spouse, Ms. You Jie. The company's shareholder landscape also includes a growing presence of institutional investors, reflecting increased market confidence and liquidity. Notable institutional stakeholders as of late 2024 and early 2025 include Prudence Investment Management (Hong Kong) Limited, holding 1.21% as of December 30, 2023, and The Vanguard Group, Inc., with 0.94% as of February 27, 2025. Other significant institutional investors such as GF Fund Management Co., Ltd. (1.07% as of June 29, 2024), Fullgoal Fund Management Co. Ltd. (0.99% as of June 29, 2024), and China Southern Asset Management Co., Ltd. (0.27% as of June 29, 2024) also maintain substantial stakes. Earlier data from Q2 2023 indicated holdings from Allianz Global Investors (approximately 5.3%), China Asset Management (approximately 4.8%), Hillhouse Capital Group (3.5%), and JPMorgan Chase & Co. (close to 2.9%). This evolving ownership structure, with a notable increase in institutional backing, supports the company's strategic direction focused on innovation and market expansion.
Key Stakeholders in Haohai Biological Technology
Understanding who owns Haohai Biological Technology involves recognizing both individual control and the growing influence of institutional investors.
- Ultimate controlling shareholders: Mr. Jiang Wei and Ms. You Jie.
- Significant institutional investors as of late 2024/early 2025 include Prudence Investment Management and The Vanguard Group.
- Other major institutional holders include GF Fund Management, Fullgoal Fund Management, and China Southern Asset Management.
- The company's dual listing on Hong Kong and Shanghai exchanges facilitates diverse ownership.
- This shift towards institutional ownership aligns with the company's Mission, Vision & Core Values of Haohai Biological Technology.
Haohai Biological Technology PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Haohai Biological Technology’s Board?
As of June 10, 2025, Shanghai Haohai Biological Technology's Board of Directors consists of eleven members. This includes four executive Directors, two non-executive Directors, and four independent non-executive Directors, alongside one staff representative Director. Dr. Hou Yongtai holds the position of Chairman of the Board.
| Director Type | Names |
|---|---|
| Chairman | Dr. Hou Yongtai |
| Executive Directors | Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi, Mr. Tang Minjie |
| Non-executive Directors | Ms. You Jie, Mr. Huang Ming, Mr. Wei Changzheng |
| Independent Non-executive Directors | Mr. Shen Hongbo, Mr. Jiang Zhihong, Mr. Su Zhi, Mr. Yang Yushe |
| Staff Representative Director | [Name not specified in provided text] |
The voting power within the company is structured around a one-share-one-vote principle for both A shares and H shares. As of June 10, 2025, there were a total of 228,733,000 shares with voting rights, comprising 190,203,760 A Shares and 38,529,240 H Shares. While this principle generally applies, Chinese regulations require separate voting by minority A Shareholders on specific resolutions to safeguard their interests. There is no public information indicating the presence of dual-class shares, golden shares, or recent significant shifts in control due to activist investor campaigns. The board's composition aims to balance operational leadership, representation from major shareholders like Ms. You Jie, and independent oversight to ensure robust corporate governance.
Understanding Haohai Biological Technology's Governance
The corporate governance structure of Haohai Biological Technology is designed to ensure accountability and strategic direction. The board's composition reflects a commitment to diverse perspectives in decision-making.
- Chairman: Dr. Hou Yongtai
- Executive management team includes key operational leaders.
- Independent Directors provide objective oversight.
- The company's voting structure adheres to a one-share-one-vote policy.
- Understanding the Revenue Streams & Business Model of Haohai Biological Technology is crucial for a complete picture of its operations.
Haohai Biological Technology Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Haohai Biological Technology’s Ownership Landscape?
Over the past three to five years, Shanghai Haohai Biological Technology has seen significant shifts in its ownership structure. These changes reflect active capital management and evolving investor confidence in the biotechnology sector.
| Development | Period | Details |
| Share Capital Increase | 2024 | 35.99% increase due to conversion of capital reserve into share capital. |
| Additional Share Issuance | June 2024 | Issued 66,782,692 capitalization shares (54,943,252 A shares, 11,839,440 H shares) from capital reserve. |
| Share Repurchases (A & H Shares) | September 2023 - June 2024 | Repurchased 45,500 H shares and 1,750,474 A shares; shares not yet cancelled. |
| Share Repurchases & Cancellations (H Shares) | March 2020 - May 2023 | 7,150,200 H shares repurchased and cancelled. |
| Restricted A Share Incentive Scheme | May, Sep, Dec 2023 & Mar 2024 | Issued 1,308,603 A shares to eligible participants. |
| Intended Shareholding Reduction | June 2024 | Lou Guoliang announced intention to reduce shareholding by up to 1.5 million shares. |
The company's ownership trends indicate a dynamic approach to managing its capital and incentivizing stakeholders. These internal adjustments are occurring alongside broader market trends, such as increased institutional investment in the biotechnology field. This suggests a growing recognition of the sector's potential by major financial players.
Institutional Investor Activity
Large financial institutions like Allianz Global Investors and The Vanguard Group are increasing their stakes. This trend highlights growing confidence in the company's future performance and the biotechnology industry as a whole.
Shareholder Actions and Capital Management
The company has actively engaged in share capital increases and repurchases. These actions, alongside incentive schemes, demonstrate a strategic effort to optimize its capital structure and align shareholder interests.
Individual Shareholder Movements
Recent announcements, such as Lou Guoliang's intention to reduce his holdings, provide insight into individual shareholder decisions. These personal financial needs can influence the short-term ownership landscape.
Ownership Evolution Overview
The company's ownership profile is evolving through a combination of capital restructuring, incentive programs, and market participation. Understanding these shifts is key to grasping the current Haohai Biological Technology ownership. For a deeper dive into the company's journey, explore its Brief History of Haohai Biological Technology.
Haohai Biological Technology Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Haohai Biological Technology Company?
- What is Competitive Landscape of Haohai Biological Technology Company?
- What is Growth Strategy and Future Prospects of Haohai Biological Technology Company?
- How Does Haohai Biological Technology Company Work?
- What is Sales and Marketing Strategy of Haohai Biological Technology Company?
- What are Mission Vision & Core Values of Haohai Biological Technology Company?
- What is Customer Demographics and Target Market of Haohai Biological Technology Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.